Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 137Recruiting 115Terminated 78Active not recruiting 78Unknown 31Withdrawn 13Not yet recruiting 10Suspended 1Enrolling by invitation 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Melanoma 2Lung Neoplasms 2Squamous Cell Carcinoma of Head and Neck 1Lymphoma 1Histiocytic Sarcoma 1Head and Neck Neoplasms 1Dendritic Cell Sarcoma, Interdigitating 1Dendritic Cell Sarcoma, Follicular 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Brain Neoplasms 1

Interventions

Nivolumab 2pembrolizumab 1osimertinib 1icotinib 1famitinib 1dabrafenib 1cemiplimab 1alirocumab 1aldesleukin 1Surgical Procedures, Operative 1Specimen Handling 1Radiotherapy 1Radiation 1Pemetrexed 1Panitumumab 1Monatide (IMS 3015) 1Magnetic Resonance Spectroscopy 1Ipilimumab 1Interleukin-2 1Injections 1Immune Checkpoint Inhibitors 1Gefitinib 1Eflornithine 1Drug Therapy 1Cisplatin 1Celecoxib 1CTLA-4 Antigen 1Blood Specimen Collection 1Biopsy 1Biological Products 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Suspended × Carcinoma, Non-Small-Cell Lung × pembrolizumab × Clear all
NCT06219174 2026-03-06

Targeting ODC as an Immunotherapeutic Target in STK11 (LKB1) Pathway-Deficient NSCLC (DFMO)

H. Lee Moffitt Cancer Center and Research Institute

Phase 1/2 Suspended
45 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡